Open Payments

Massachusetts General Hospital

Type
Teaching hospital
Where
Boston, MA
Medicare CCN
220071
Received
$91,550,024 in 2,926 records, 2024 ($40,023,757 general, $51,526,266 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment611$40,023,757
2024Research payment2,315$51,526,266

By company

CompanyRecordsAmountYears
Takeda Pharmaceuticals U.S.A., Inc.114$29,217,9982024
E.R. Squibb & Sons, L.L.C.18$4,577,8162024
Amgen Inc.22$3,745,0482024
PFIZER INC.55$3,622,3442024
Janssen Research & Development, LLC55$3,592,0982024
Illumina, Inc.2$3,347,5842024
Genentech, Inc.66$2,943,0832024
SANOFI US SERVICES INC.30$2,577,5002024
Servier BioInnovation80$2,349,5072024
GE HEALTHCARE18$2,267,7602024
Stryker Corporation8$2,156,0822024
BeiGene, Ltd.17$1,675,0182024
GlaxoSmithKline, LLC.23$1,671,7732024
Iovance Biotherapeutics, Inc.33$1,648,6452024
Biogen, Inc.22$1,356,3932024
Boston Scientific Corporation70$1,221,5372024
ModernaTX, Inc.88$1,099,0842024
Zimmer Biomet Holdings, Inc.4$1,030,8442024
ABBVIE INC.33$967,9342024
Regeneron Pharmaceuticals, Inc.54$909,5572024
Canon Medical Systems Corporation3$876,2772024
Edwards Lifesciences Corporation56$852,7842024
ARGENX US, INC.5$787,7232024
United Therapeutics Corporation36$645,6042024
Sarepta Therapeutics, Inc.2$613,0652024
AstraZeneca Pharmaceuticals LP11$589,8592024
Tanabe Pharma America, Inc.19$550,7192024
Medacta USA, Inc.1$522,1352024
OMNIlife science, Inc6$516,0072024
TransMedics, Inc.10$468,9652024
GENZYME CORPORATION16$414,3572024
Daiichi Sankyo Inc.5$395,1262024
Dr.Reddy's Laboratories,Inc.6$385,4572024
Kite Pharma, Inc.2$383,4712024
Gilead Sciences, Inc.14$383,1872024
JAZZ PHARMACEUTICALS INC.41$324,5592024
Amylyx Pharmaceuticals, Inc.37$315,7472024
Alkermes, Inc.1$315,4672024
Boehringer Ingelheim International GmbH10$305,8922024
Heidelberg Engineering, Inc.1$300,0002024
Octapharma USA, Inc.13$288,7822024
Haemonetics Corporation34$276,4092024
Medtronic, Inc.74$275,5232024
Concordia Pharmaceuticals Inc.3$255,0002024
Cook Research Incorporated9$253,4982024
ARRAY BIOPHARMA INC2$237,2342024
Otsuka Pharmaceutical Co., Ltd.3$235,7722024
Cala Health, Inc.12$222,0922024
Sage Therapeutics, LLC3$219,4432024
Beckman Coulter, Inc.3$215,4162024

By nature of payment

NatureRecordsAmount
Research payment2,315$51,526,266
Royalty or License110$35,857,905
Grant36$1,794,471
Compensation for services other than consulting, including serving as faculty or as a speaker at a v22$1,505,216
Consulting Fee25$323,938
Space rental or facility fees (teaching hospital only)9$240,862
Long term medical supply or device loan40$170,671
Debt forgiveness361$95,468
Education6$30,800
Charitable Contribution2$4,423

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31OCCLUTECH US LLC$78,726Grant (9 payments)Cash or cash equivalent2024
2024-12-31Merck Sharp & Dohme LLC$66,420Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 2,3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 mRNA-4157 in com2024
2024-12-31Siemens Medical Solutions USA, Inc.$50,960Research paymentIn-kind items and servicesBiograph Vision 600 (8 Ring/64 CT) Device, MI - Nuclear Medicine (incl. PETNET & MIBR)Case Studies and Publications on Biograph Vision2024
2024-12-31Philips North America LLC$20,000Royalty or LicenseCash or cash equivalent(1399) MRI Equip Undiv Device, Medical Device2024
2024-12-31Intuitive Surgical, Inc.$18,800Long term medical supply or device loanIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Haemonetics Corporation$9,600Research paymentIn-kind items and servicesTEG6S HEMOSTASIS SYSTEM Device, DEVICESTHE USE OF THROMBOELASTOGRAPHY WITH PLATELET MAPPING TO GUIDE THROMBOPHYLAXIS FOLLOWING LOWER EXTREMITY REVASCULARIZATIO2024
2024-12-31Cambridge Interventional LLC$6,000Long term medical supply or device loanIn-kind items and servicesCRF Device, RFA2024
2024-12-31AngioDynamics, Inc.$4,800Long term medical supply or device loanIn-kind items and servicesVenaCure 1470 Pro Device, ET2024
2024-12-31Stryker Corporation$4,445Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2024
2024-12-31Stryker Corporation$4,445Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2024
2024-12-31Stryker Corporation$4,445Long term medical supply or device loanIn-kind items and servicesPROCUITY Device, PATIENT HANDLING - PH2024
2024-12-31Siemens Medical Solutions USA, Inc.$4,248Research paymentIn-kind items and servicesACUSON Sequoia Diagnostic Ultrasound System Device, US - Ultrasound SystemsNoninvasive Biomarkers of Metabolic Liver Disease NIMBLE Study112024
2024-12-31Intuitive Surgical, Inc.$2,500EducationIn-kind items and servicesDAVINCI XI Device, SURGERY2024
2024-12-31Siemens Medical Solutions USA, Inc.$1,865Research paymentCash or cash equivalentsyngo Dynamics Device, SY - Image and Knowledge Management2024
2024-12-31COLOPLAST CORP$1,844Debt forgivenessCash or cash equivalentTitan Device, Men's Health2024
2024-12-31AstraZeneca Pharmaceuticals LP$1,563Research paymentIn-kind items and servicesA Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate2024
2024-12-31Impulse Dynamics (USA) Inc.$1,000Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-12-31Impulse Dynamics (USA) Inc.$1,000Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2024
2024-12-31ABBVIE INC.$882Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYM14-658 UPA UC Ph3 Peds2024
2024-12-31Masimo Corporation$857Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Stryker Corporation$745Long term medical supply or device loanIn-kind items and servicesNA Device, PATIENT HANDLING - PH2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$642Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31Masimo Corporation$577Long term medical supply or device loanCash or cash equivalentSET and rainbow SET Device, Devices2024
2024-12-31ABBVIE INC.$525Research paymentIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGYM16-194 Skyrizi Ph3 PIP CD2024
2024-12-31ABBVIE INC.$300Research paymentIn-kind items and servicesM23-362 Ph2 Epcoritamab RR DLBCL and FL Outpatient Study2024
2024-12-31Masimo Corporation$291Long term medical supply or device loanCash or cash equivalentrainbow Acoustic Monitoring Device, Devices2024
2024-12-31Masimo Corporation$285Long term medical supply or device loanCash or cash equivalentSedLine Device, Devices2024
2024-12-31AstraZeneca Pharmaceuticals LP$203Research paymentIn-kind items and servicesLOKELMA Drug, Cardiovascular and MetabolismTA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descrip2024
2024-12-31Fisher & Paykel Healthcare Inc$122Long term medical supply or device loanIn-kind items and servicesFISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier2024
2024-12-31Alnylam Pharmaceuticals Inc.$48Research paymentIn-kind items and servicesA Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1)2024
2024-12-30PFIZER INC.$240,000Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYEVIDENCE GENERATION STUDY TREATMENT AND CLINICAL CHARACTERISTICS OF PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTA2024
2024-12-30QIAGEN, LLC$4,660Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$1,385Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$874Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$619Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$599Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$384Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$383Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$351Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$346Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$317Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$313Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$313Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$300Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$299Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$296Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$285Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$279Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$274Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$274Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$251Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$241Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$235Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$222Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$222Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$213Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$202Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$194Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$168Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$156Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$151Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$93Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$71Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$71Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$29Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$24Debt forgivenessCash or cash equivalent2024
2024-12-30QIAGEN, LLC$5Debt forgivenessCash or cash equivalent2024
2024-12-28JAZZ PHARMACEUTICALS INC.$85,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-12-27Janssen Research & Development, LLC$40,192Consulting FeeCash or cash equivalent2024
2024-12-27Intuitive Surgical, Inc.$12,207Royalty or LicenseCash or cash equivalentDa Vinci Surgical System Device, SURGERY2024
2024-12-27Intuitive Surgical, Inc.$8,342Royalty or LicenseCash or cash equivalentDa Vinci Surgical System Device, SURGERY2024
2024-12-26BeiGene, Ltd.$347,760Research paymentIn-kind items and servicesBRUKINSA Drug, OncologyA Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell 2024
2024-12-24Amgen Inc.$395,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-24GlaxoSmithKline, LLC.$87,968Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGY00000000000000000000000000000000000000000000000000000000000000002144382024
2024-12-24United Therapeutics Corporation$7,800Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24United Therapeutics Corporation$5,720Research paymentCash or cash equivalentTYVASO Drug, Idiopathic Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2024
2024-12-24GlaxoSmithKline, LLC.$1,133Research paymentIn-kind items and servicesJEMPERLI Biological, ONCOLOGY00000000000000000000000000000000000000000000000000000000000000002144382024
2024-12-23E.R. Squibb & Sons, L.L.C.$5,600Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularA Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients with an Elevated D-Dimer2024
2024-12-23Genentech, Inc.$2,850Research paymentCash or cash equivalentA Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease2024
2024-12-23Edwards Lifesciences Corporation$1,820Research paymentCash or cash equivalentTRISCEND II Pivotal (2020-05)2024
2024-12-23Bausch Health US, LLC$1,487Research paymentCash or cash equivalentXIFAXAN Drug, GastroenterologyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-12-20Janssen Research & Development, LLC$245,100Research paymentCash or cash equivalentA Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of A2024
2024-12-20PTC Therapeutics, Inc.$12,352Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-20PROGENICS PHARMACEUTICALS, INC.$9,862Research paymentCash or cash equivalentPYLARIFY Drug, RADIOPHARMACEUTICALPYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR2024
2024-12-20W. L. Gore & Associates, Inc.$4,770Research paymentCash or cash equivalentGORE CARDIOFORM Septal Occluder Device, DevicesGORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with P2024
2024-12-20BIOTRONIK INC.$1,500Research paymentCash or cash equivalentOrsiro Mission Device, Cardiology/Vascular DiseasesBIOFLOW-VII2024
2024-12-20Medtronic, Inc.$1,500GrantCash or cash equivalentINFUSE BONE GRAFT Device, Bone Matrix/Graft2024
2024-12-19BeiGene, Ltd.$151,200Research paymentIn-kind items and servicesBRUKINSA Drug, OncologyA Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell 2024
2024-12-19E.R. Squibb & Sons, L.L.C.$129,631Research paymentCash or cash equivalentORENCIA Biological, ImmunologyCVID (Common Variable Immune Deficiency) USID Net Registry Extension Study2024
2024-12-19Chiesi USA, Inc.$70,080GrantCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHY2024
2024-12-19Janssen Research & Development, LLC$68,542Consulting FeeCash or cash equivalent2024
2024-12-19PFIZER INC.$33,750Research paymentCash or cash equivalentPFIZER TRANSLATIONAL NEUROSCIENCE PTN FELLOWSHIP PROGRAM2024
2024-12-19Takeda Pharmaceuticals U.S.A., Inc.$25,968Research paymentIn-kind items and servicesNINLARO Drug, ONCOLOGYX16104: A PHASE II STUDY OF IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE, AND DARATUMUMAB IN TRANSPLANT-INELIGIBLE PATIENTS WIT2024
2024-12-19Janssen Research & Development, LLC$20,258Consulting FeeCash or cash equivalent2024
2024-12-19Ardelyx, Inc.$9,262Consulting FeeCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGY2024
2024-12-19Bausch Health US, LLC$3,178Research paymentCash or cash equivalentCancer prevention with laser: a pilot study to determine if fractional nonablative laser can alter dermal IGF-1 expressi2024
2024-12-19Janssen Research & Development, LLC$1,605Research paymentCash or cash equivalentA Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ62024
2024-12-18GE HEALTHCARE$1,185,741Research paymentCash or cash equivalentDEFINE/DEVELOP LEARNING PLATFORM2024
2024-12-18PFIZER INC.$18,500Research paymentCash or cash equivalentPREVNAR 13 Biological, VACCINESCONJUGATE VS CARBOHYDRATE VACCINE COMPARATIVE STUDYWI2335032024
2024-12-18Bolton Medical Inc$16,350Research paymentCash or cash equivalentRELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM Device, ENDOVASCULAR AORTIC REPAIREXTEND2024
2024-12-18Tanabe Pharma America, Inc.$3,191Research paymentCash or cash equivalentA PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILIT2024
2024-12-18Chiesi USA, Inc.$1,628Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Chiesi USA, Inc.$1,616Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Chiesi USA, Inc.$1,217Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Chiesi USA, Inc.$1,122Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Chiesi USA, Inc.$1,001Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Chiesi USA, Inc.$503Research paymentCash or cash equivalentMYALEPT Drug, GENERALIZED LIPODYSTROPHYStudy to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with PL (METRE-PL)2024
2024-12-18Cala Health, Inc.$416Research paymentIn-kind items and servicesThe wandering nerve; gateway to boost Alzheimer's disease related cognitive performance2024
2024-12-18Cala Health, Inc.$259Research paymentIn-kind items and servicesThe wandering nerve; gateway to boost Alzheimer's disease related cognitive performance2024
2024-12-18Cala Health, Inc.$130Research paymentIn-kind items and servicesBrain Mechanisms of Vagus Nerve Stimulation and Stress Reduction Training for Migraine2024
2024-12-18QIAGEN, LLC$77Debt forgivenessCash or cash equivalent2024
2024-12-18QIAGEN, LLC$46Debt forgivenessCash or cash equivalent2024
2024-12-18QIAGEN, LLC$29Debt forgivenessCash or cash equivalent2024
2024-12-17PTC Therapeutics, Inc.$50,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-17PTC Therapeutics, Inc.$7,943Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-17Ultragenyx Pharmaceutical Inc.$6,935Research paymentCash or cash equivalentUX701-CL3012024
2024-12-17Boston Scientific Corporation$3,133Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIOCCLUDE2024
2024-12-17Takeda Pharmaceuticals U.S.A., Inc.$600Research paymentCash or cash equivalentPARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM2024
2024-12-17PTC Therapeutics, Inc.$452Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-17Medtronic, Inc.$90Research paymentCash or cash equivalentADAPT-PD Trial2024
2024-12-16SANOFI US SERVICES INC.$97,539Research paymentCash or cash equivalent2024
2024-12-16TransMedics, Inc.$70,480Compensation for services other than consulting, including serving as faculty or as a speaker at a v (12 payments)Cash or cash equivalentOrgan Care System Device, Device2024
2024-12-16Servier BioInnovation$43,869Research paymentIn-kind items and servicesTibsovo Drug, OncologySTUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA2024
2024-12-16Servier BioInnovation$43,869Research paymentIn-kind items and servicesTibsovo Drug, OncologySTUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA2024
2024-12-16Janssen Research & Development, LLC$39,802Research paymentCash or cash equivalentA Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 2024
2024-12-16Janssen Research & Development, LLC$25,480Research paymentCash or cash equivalentA Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 2024
2024-12-16SANOFI US SERVICES INC.$24,640Research paymentCash or cash equivalentAn Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient2024
2024-12-16Insmed, Inc.$2,335Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2024
2024-12-16Biosense Webster, Inc.$2,298Research paymentCash or cash equivalentAssessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla2024
2024-12-16Insmed, Inc.$2,141Research paymentCash or cash equivalentA Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety2024
2024-12-16QIAGEN, LLC$52Debt forgivenessCash or cash equivalent2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$49,096Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$8,978Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13Calyxo, Inc.$8,019Royalty or LicenseCash or cash equivalentCVAC ASPIRATION SYSTEM Device, Urology2024
2024-12-13Biosense Webster, Inc.$5,788Research paymentCash or cash equivalentTHERMOCOOL SMARTTOUCH Device, CardiologySafety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre2024
2024-12-13W. L. Gore & Associates, Inc.$4,537Research paymentCash or cash equivalentProduct in Development Device, DevicesGORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter cl2024
2024-12-13Takeda Pharmaceuticals U.S.A., Inc.$1,500Research paymentCash or cash equivalentA STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT2024
2024-12-13W. L. Gore & Associates, Inc.$898Research paymentCash or cash equivalentProduct in Development Device, DevicesGORE CARDIOFORM Septal Occluder Migraine Clinical Study: A Study to evaluate the safety and efficacy of transcatheter cl2024
2024-12-13Merit Medical Systems Inc$460Debt forgivenessCash or cash equivalent2024
2024-12-13Merit Medical Systems Inc$405Debt forgivenessCash or cash equivalent2024
2024-12-12Sage Therapeutics, LLC$99,042Research paymentCash or cash equivalentNational Pregnancy Registry for Psychiatric Medications2024
2024-12-12Edwards Lifesciences Corporation$26,236Research paymentCash or cash equivalentTHE ENCIRCLE Trial (#2018-19)2024
2024-12-12Roche Diagnostics Operations, Inc.$26,110Research paymentCash or cash equivalentElecsys Troponin T Gen 5 STAT Device, CardiovascularRD0062632024
2024-12-12Biogen, Inc.$15,000GrantCash or cash equivalent2024
2024-12-12Roche Diagnostics Operations, Inc.$9,798Research paymentCash or cash equivalentElecsys Troponin T Gen 5 STAT Device, CardiovascularRD0062632024
2024-12-12Genentech, Inc.$5,891Research paymentCash or cash equivalentOcrevus Biological, ImmunologyOcrelizumab PPMS High Dose Study2024
2024-12-12Takeda Pharmaceuticals U.S.A., Inc.$1,200Research paymentCash or cash equivalentPARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM2024
2024-12-12Takeda Pharmaceuticals U.S.A., Inc.$600Research paymentCash or cash equivalentPARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM2024
2024-12-12Abbott Laboratories$25Research paymentIn-kind items and servicesFLEXABILITY Device, ELECTROPHYSIOLOGYVT PAS Study2024
2024-12-11JAZZ PHARMACEUTICALS INC.$15,127Research paymentCash or cash equivalentEPIDIOLEX Drug, NEUROLOGYAn Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solu2024
2024-12-11SANOFI US SERVICES INC.$5,150Research paymentCash or cash equivalentFABRAZYME Biological, Genetic DiseaseFabry Disease Registry Protocol2024
2024-12-11Medtronic, Inc.$2,068Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-11Bausch Health US, LLC$419Research paymentCash or cash equivalentXIFAXAN Drug, GastroenterologyA Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble2024
2024-12-11Medtronic, Inc.$124Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-11Medtronic, Inc.$124Research paymentCash or cash equivalentAURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs)PSR-CVG2024
2024-12-10Servier BioInnovation$79,766Research paymentIn-kind items and servicesPhase 1 Astrocytoma study which is a study looking at the combination of Vorasidenib and Pembrolizumab2024
2024-12-10Boston Scientific Corporation$4,862Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICACURATE IDE2024
2024-12-10Cook Research Incorporated$4,000Research paymentCash or cash equivalentCMH-17072024
2024-12-10United Therapeutics Corporation$3,422Research paymentCash or cash equivalentTYVASO Drug, Progressive Pulmonary FibrosisA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2024
2024-12-10Boston Scientific Corporation$2,300Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2024
2024-12-10Boston Scientific Corporation$983Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIHI-PEITHO2024
2024-12-10Boston Scientific Corporation$250Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2024
2024-12-09BeiGene, Ltd.$90,720Research paymentIn-kind items and servicesBRUKINSA Drug, OncologyA Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell 2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09Servier BioInnovation$21,934Research paymentIn-kind items and servicesVoranigo Drug, OncologySTUDY OF VORASIDENIB, AG-881, IN PARTICIPANTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1 OR IDH2 MUTATION, I2024
2024-12-09SANOFI US SERVICES INC.$17,195Research paymentCash or cash equivalentAn Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient2024
2024-12-09SANOFI US SERVICES INC.$16,080Research paymentCash or cash equivalent2024
2024-12-09Medtronic, Inc.$2,955Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-12-09Medtronic, Inc.$2,955Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2024
2024-12-09Edwards Lifesciences Corporation$1,040Research paymentCash or cash equivalentCLASP II TR Pivotal, Study No. 2019-072024
2024-12-06SANOFI US SERVICES INC.$113,286Research paymentCash or cash equivalentAn Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008) on Safety and Disease Activity in Patient2024
2024-12-06Regeneron Pharmaceuticals, Inc.$54,297Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PA2024
2024-12-06RECORDATI_RARE_DISEASES_INC.$1,000Research paymentCash or cash equivalentOSILODROSTAT Drug, ENDOCRINE AGENTLCI699-RECAG-PASS-05722024
2024-12-05PFIZER INC.$300,000Research paymentCash or cash equivalentPSYCHOMETRIC VALIDATION OF A NEW LONG COVID PATIENT REPORTED OUTCOMES PRO INSTRUMENT PROSPECTIVE OBSERVATIONAL STUDY FOR2024
2024-12-05Zimmer Biomet Holdings, Inc.$127,672Research paymentCash or cash equivalentVanguard Complete Knee Solution Device, KneesStudy Management for E1 Tibial Bearing Study2024
2024-12-05Edwards Lifesciences Corporation$23,007Research paymentCash or cash equivalentThe PROGRESS Trial – Continued Access 2021-01-CAP2024
2024-12-05NIDEK CO., LTD.$20,000Royalty or LicenseCash or cash equivalent2024
2024-12-05Cala Health, Inc.$14,400Research paymentIn-kind items and servicesEvaluation of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation on the Modulation of Disease Activity and Inf2024
2024-12-05JAZZ PHARMACEUTICALS INC.$8,500Research paymentCash or cash equivalentEPIDIOLEX Drug, NEUROLOGYEvaluation of Cannabidiol for Reduction of Brain Neuroinflammation2024
2024-12-05Boehringer Ingelheim Pharmaceuticals, Inc.$3,832Research paymentCash or cash equivalentBI 1015550 - Ph3 Open Label Extension2024
2024-12-05Roche Diagnostics Operations, Inc.$3,747Research paymentCash or cash equivalentElecsys Troponin T Gen 5 STAT Device, CardiovascularRD0062632024
2024-12-05BIOTRONIK INC.$298Research paymentCash or cash equivalentActicor 7 VR-T DX Device, Cardiology/Vascular DiseasesBIO-LIBRA2024
2024-12-05BIOTRONIK INC.$298Research paymentCash or cash equivalentPlexa ProMRI Device, Cardiology/Vascular DiseasesBIO-LIBRA2024

The latest 200 records of 2,926.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Suffolk CountyBoston city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Boston, MA, county Suffolk County, MA, state Massachusetts; placed by its city name.

MeasurePlace (city or town)
Boston, MA
County
Suffolk County, MA
State
Massachusetts
Population B01003666,442785,1217,044,056
Population, 2020 census P1675,647797,9367,029,917
Median age B0100233.333.940.0
Under 18 B0100115.1%16.0%19.4%
65 and over B0100113.0%13.3%17.9%
Households B11001283,374327,1672,785,042
Foreign born B0500227.8%29.8%18.0%
Median household income B19013$97,344$95,631$103,960
Median family income B19113$116,436$112,072$131,675
Per capita income B19301$61,698$58,636$57,897
Poverty rate B1700116.6%16.2%10.0%
Unemployment rate B230256.1%6.3%5.2%
Civilian labor force B23025402,354468,6363,911,446
Mean commute (minutes) B0801330.330.929.1
Bachelor's degree or higher B1500354.9%50.6%47.3%
Housing units B25001310,625357,2903,030,406
Owner-occupied B2500335.7%36.5%62.5%
Renters B2500364.3%63.5%37.5%
Median home value B25077$731,700$705,800$562,100
Median gross rent B25064$2,147$2,129$1,762
White, not Hispanic B0300244.1%43.6%66.6%
Black B0300219.3%17.1%6.4%
Hispanic or Latino B0300219.3%23.2%13.3%
Asian B0300210.3%9.2%7.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Boston, MA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.